Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...
This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...
Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results